Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese
× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

Plateued response on second generation TKI

More
9 years 9 months ago #923 by joannehickey
Plateued response on second generation TKI was created by joannehickey
I have a 60 year old woman diagnosed chronic phase CML March 2012. She has a history of hypertension only. She started nilotinib April 2012. Within one month she had achieved a CHR but also developed a Grade III transaminitis requiring hold of the drug. This resolved within few weeks and I restarted at reduced dose as per the monograph. She developed recurrent significant transaminitis. I changed to Dasatinib in September 2012. She achieved a complete cytogenetic response by September 2013, however at 18 months (March 2014) she still had not achieved an MMR – BCR-ABL IS of 0.139. Serial measurement shows persistent CCR with most recent BCR-ABL IS of 0.239 (June 2014). Mutational analysis of BCR-ABL is negative. Bone marrow confirms CCR and does not demonstrate any new cytogenetic abnormalities. Her sibs are being typed. She is a very risk averse individual when it comes to therapy and wishes to simply continue to follow along. I had considered increasing the dose of Dasatinib. I am unsure of the role of the newer TKI’s here. I wonder what other’s approach to this situation would be.
Quick Reply

Reply to joannehickey

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
  • Giuseppe Saglio
  • Giuseppe Saglio's Avatar
9 years 9 months ago #945 by Giuseppe Saglio
Replied by Giuseppe Saglio on topic Plateued response on second generation TKI
The patient showed a slow response to nilotinib therapy, in part due to the onset of toxicity that hampered a correct assumption and finally lead to discontinuation of the initially chosen drug. At the moment, even after switching to Dasatinib, the patient shows a persistent suboptimal response, lacking the achievement of MMR. However for the moment I would not change the therapy as there is no loss of CCyR and therefore no overt failure. For the same reason and due to the age of the patient, I would not consider the option of an alloSCT. I would follow this patient carefully and would check about her compliance to therapy, maybe related to fears related to the previous toxicity .
Quick Reply

Reply to Giuseppe Saglio

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
  • Jeff Lipton
  • Jeff Lipton's Avatar
9 years 9 months ago #947 by Jeff Lipton
Replied by Jeff Lipton on topic Plateued response on second generation TKI
Agree with Prof Saglio. So long as she has sustained CCyR, would not change. It should be noted as well, that on occasion, some patients exhibit a two phase response and after a plateau in response such as this, a subsequent response improvement after a period of time, even years, can sometimes be observed.
Quick Reply

Reply to Jeff Lipton

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
Moderators: Nicola, arlene